Product name | phenobarbital |
---|
Product number | - |
---|---|
Other names | Phenylethylbarbiturate |
Identified uses | For industry use only. |
---|---|
Uses advised against | no data available |
Company | MOLBASE (Shanghai) Biotechnology Co., Ltd. |
---|---|
Address | Floor 4 & 5, Building 12, No. 1001 North Qinzhou Road, Xuhui District, Shanghai, China |
Telephone | +86(21)64956998 |
Fax | +86(21)54365166 |
Emergency phone number | +86-400-6021-666 |
---|---|
Service hours | Monday to Friday, 9am-5pm (Standard time zone: UTC/GMT +8 hours). |
Acute toxicity - Oral, Category 3
Skin sensitization, Category 1
Carcinogenicity, Category 2
Reproductive toxicity, Category 1B
2.2 GHS label elements, including precautionary statementsPictogram(s) | |
---|---|
Signal word | Danger |
Hazard statement(s) | H301 Toxic if swallowed H317 May cause an allergic skin reaction H351 Suspected of causing cancer H360 May damage fertility or the unborn child |
Precautionary statement(s) | |
Prevention | P264 Wash ... thoroughly after handling. P270 Do not eat, drink or smoke when using this product. P261 Avoid breathing dust/fume/gas/mist/vapours/spray. P272 Contaminated work clothing should not be allowed out of the workplace. P280 Wear protective gloves/protective clothing/eye protection/face protection. P201 Obtain special instructions before use. P202 Do not handle until all safety precautions have been read and understood. |
Response | P301+P310 IF SWALLOWED: Immediately call a POISON CENTER/doctor/… P321 Specific treatment (see ... on this label). P330 Rinse mouth. P302+P352 IF ON SKIN: Wash with plenty of water/... P333+P313 If skin irritation or rash occurs: Get medical advice/attention. P362+P364 Take off contaminated clothing and wash it before reuse. P308+P313 IF exposed or concerned: Get medical advice/ attention. |
Storage | P405 Store locked up. |
Disposal | P501 Dispose of contents/container to ... |
none
3.Composition/information on ingredients 3.1 SubstancesChemical name | Common names and synonyms | CAS number | EC number | Concentration |
---|---|---|---|---|
phenobarbital | phenobarbital | 50-06-6 | none | 100% |
Consult a physician. Show this safety data sheet to the doctor in attendance.
If inhaledIf breathed in, move person into fresh air. If not breathing, give artificial respiration. Consult a physician.
In case of skin contactWash off with soap and plenty of water. Consult a physician.
In case of eye contactRinse thoroughly with plenty of water for at least 15 minutes and consult a physician.
If swallowedNever give anything by mouth to an unconscious person. Rinse mouth with water. Consult a physician.
4.2 Most important symptoms/effects, acute and delayedSYMPTOMS: Symptoms of exposure to this class of compounds via ingestion include sedation, nystagmus, ataxia, irritability and hyperexcitability in children, exfoliative dermatitis and hypoprothrombinemia in the neonate. Other symptoms via ingestion include confusion and restlessness in the elderly or in the presence of pain; respiratory depression, occasional allergic reactions, particularly affecting the skin; maculopapular skin rash, fixed-drug eruptions purpura, photosensitivity, erythema multiforme (the Stevens-Johnson syndrome), toxic epidermal necrolysis, hypothermia with associated pyrexia during recovery; hepatitis, cholestasis, nephritis, hepatic dysfunction and shoulder-hand syndrome. Ingestion may cause agitation in the elderly, hemorrhage in the neonate, morbilliform or scarlatiniform rash, megaloblastic anemia and osteomalacia. Ingestion can also cause sleepiness, unsteadiness, mental confusion, slow and shallow respiration, flaccid muscles, hypotension, cyanosis, hyperthermia, absent reflexes and coma. The duration of coma is dependent on the dose. Cerebral edema contributes to the persistence of coma. If coma persists, moist rales are heard in the lower lung fields, indicating pulmonary edema. Atelectasis or aspiration pneumonia with signs of lung consolidation and fever can also occur. Carbon dioxide retention under these conditions can cause acidosis. Death may occur from pneumonia, pulmonary edema or refractory hypotension. Other symptoms of exposure may include drowsiness, headache, irregular respiration and central nervous system effects Inhalation of the dust may cause irritation of the upper respiratory tract. Hypnosis and excitement have been reported. Other reported symptoms include delirium and deep unconsciousness. It can cause poor judgment and hangover. Chronic symptoms include effects on neurological and pyschic functions, disorientation, skin rash, ataxia, dizziness, depression an foliate deficiency. Chronic exposure may also result in drowsiness, emotional lability, irritability, neglect of personal appearance and other behavior disturbances. Other symptoms of chronic exposure are nystagmus, tremor, mild changes in mental condition such as loss of memory, inability to concentrate, giddiness, depression and dullness of mental perception, and precipitation of acute porphyria. Overdosage may cause hemorrhagic and erythematous bullae, respiratory depression, cardiovascular depression, hypotension and shock leading to renal failure; prolonged coma and death due t respiratory or circulatory failure. Absent bowel sounds are a sign of severe poisoning and their return sometimes indicates further absorption of any remaining compound in the gastrointestinal tract with resultant relapse. Dangerous central nervous system effects occur in children at 10 mg/kg. It causes respiratory depression in the neonate and diminished milk flow in the nursing mother. Eye effects through ingestion include slow eye reaction to light, mydriasis, miosis, bilateral ptosis, rapid fluttering of the eyelids, disturbance of eye movement, weakness of convergence, weakness of vertical gaze and of individual extraocular muscles and transient loss of vision following coma. There has been one case of spontaneous abortion. Exposure to this compound may also cause somnolence, motor activity changes, pulmonary changes, allergic dermatitis, fever, developmental abnormalities of the central nervous system, body wall, musculoskeletal, respiratory, gastrointestinal and urogenital systems. It may also cause jaundice. This compound may increase the metabolism of other drugs. Pyschic or physical dependence may occur with continued use. Abrupt withdrawal may result in severe abstinence syndrome which includes grand mal seizures and delirium. ACUTE/CHRONIC HAZARDS: This compound is highly toxic by ingestion. It is also toxic if absorbed through the skin. It is harmful by inhalation and may cause irritation by skin or eye contact. When heated to decomposition it emits toxic fumes of nitrogen oxides.
4.3 Indication of immediate medical attention and special treatment needed, if necessaryTreatment of overdosage is mainly supportive including maintenance of an adequate airway and assisted respiration and oxygen administration if needed. Resuscitative measures should be initiated promptly. Standard treatment for shock should be administered if necessary. Management of hypotension may include administration of iv fluids, elevation of the lower extremities, and/or use of vasopressor or inotropic agents. For seizures, iv diazepam and phenytoin may be used; in case of refractory seizures, general anesthesia and paralysis induced by a neuromuscular blocking agent may be necessary. Activated charcoal is an effective barbiturate adsorbant when administered within 30 minutes following ingestion of the drugs. ... Gastric aspiration is not recommended unless there is evidence that the drug has been ingested recently (within 4 hours); care should be taken to prevent pulmonary aspiration of gastric contents. Multiple-dose, nasogastric administration of activated charcoal has been used effectively to treat phenobarbital overdose; activated charcoal enhances elimination of the drug and shortens the duration of coma. The patient's vital signs, fluid intake, blood gases, and serum electrolytes should be monitored closely. Analeptic drugs should not be administered because they may produce paroxysmal cerebral activity which may result in generalized seizures. In addition, it has been demonstrated that analeptics are incapable of stimulating respiration and exerting an arousal effect in patients with severe barbiturate poisoning and profound CNS depression. If renal function is normal, forced diuresis may be of benefit. In addition, alkalinization of the urine increases renal excretion of phenobarbital, aprobarbital, and mephobarbital which is metabolized to phenobarbital. Peritoneal dialysis or hemodialysis may be useful in severe barbiturate intoxication and/or if the patient is anuric or in shock. /Barbiturates General Statement/
5.Fire-fighting measures 5.1 Extinguishing media Suitable extinguishing mediaWater spray, dry chemical, carbon dioxide, or foam as appropriate for surrounding fire and materials.
5.2 Specific hazards arising from the chemicalThis chemical is combustible.
5.3 Special protective actions for fire-fightersWear self-contained breathing apparatus for firefighting if necessary.
6.Accidental release measures 6.1 Personal precautions, protective equipment and emergency proceduresUse personal protective equipment. Avoid dust formation. Avoid breathing vapours, mist or gas. Ensure adequate ventilation. Evacuate personnel to safe areas. Avoid breathing dust. For personal protection see section 8.
6.2 Environmental precautionsPrevent further leakage or spillage if safe to do so. Do not let product enter drains. Discharge into the environment must be avoided.
6.3 Methods and materials for containment and cleaning upWipe up spillage or collect spillage using a high- efficiency vacuum cleaner. Avoid breathing dust. Wash spill site. Place spillage and all contaminated cleanup materials in a thick plastic hazardous waste disposal bag or leakproof container and label it CAUTION: HAZARDOUS CHEMICAL WASTE.
7.Handling and storage 7.1 Precautions for safe handlingAvoid contact with skin and eyes. Avoid formation of dust and aerosols. Avoid exposure - obtain special instructions before use.Provide appropriate exhaust ventilation at places where dust is formed. For precautions see section 2.2.
7.2 Conditions for safe storage, including any incompatibilitiesStore in tight container as defined in the USP-NF. This material should be handled and stored per label instructions to ensure product integrity.
8.Exposure controls/personal protection 8.1 Control parameters Occupational Exposure limit valuesno data available
Biological limit valuesno data available
8.2 Appropriate engineering controlsHandle in accordance with good industrial hygiene and safety practice. Wash hands before breaks and at the end of workday.
8.3 Individual protection measures, such as personal protective equipment (PPE) Eye/face protectionSafety glasses with side-shields conforming to EN166. Use equipment for eye protection tested and approved under appropriate government standards such as NIOSH (US) or EN 166(EU).
Skin protectionWear impervious clothing. The type of protective equipment must be selected according to the concentration and amount of the dangerous substance at the specific workplace. Handle with gloves. Gloves must be inspected prior to use. Use proper glove removal technique(without touching glove's outer surface) to avoid skin contact with this product. Dispose of contaminated gloves after use in accordance with applicable laws and good laboratory practices. Wash and dry hands. The selected protective gloves have to satisfy the specifications of EU Directive 89/686/EEC and the standard EN 374 derived from it.
Respiratory protectionWear dust mask when handling large quantities.
Thermal hazardsno data available
9.Physical and chemical propertiesPhysical state | Crystalline Solid |
---|---|
Colour | Crystals (3 different phases) |
Odour | Odorless |
Melting point/ freezing point | 174ºC |
Boiling point or initial boiling point and boiling range | no data available |
Flammability | no data available |
Lower and upper explosion limit / flammability limit | no data available |
Flash point | 11 °C |
Auto-ignition temperature | no data available |
Decomposition temperature | no data available |
pH | Saturated soln in water has a pH of about 5 |
Kinematic viscosity | no data available |
Solubility | >34.8 [ug/mL] |
Partition coefficient n-octanol/water (log value) | no data available |
Vapour pressure | 1.4X10-11 mm Hg at 25°C (est) |
Density and/or relative density | 1.234 g/cm3 |
Relative vapour density | no data available |
Particle characteristics | no data available |
no data available
10.2 Chemical stabilityAqueous solutions of "phenobarbital" sodium are not generally stable. The drug is more stable in polyethylene glycol or propylene glycol.
10.3 Possibility of hazardous reactionsPHENOBARBITAL is also sensitive to prolonged exposure to light. Incompatible with strong oxidizing agents. Forms a complex of reduced solubility with macrogol 4000. Able to form metal derivatives .
10.4 Conditions to avoidno data available
10.5 Incompatible materialsSolutions of "phenobarbital" sodium should not be added to acidic solutions because precipitation of "phenobarbital" may occur. Solutions for injection should not be used if they contain a precipitate.
10.6 Hazardous decomposition productsWhen heated to decomposition it emits toxic fumes of /nitrogen oxides/.
11.Toxicological information Acute toxicity- Oral: LD50 rat oral 162 +/- 14 mg/kg
- Inhalation: no data available
- Dermal: no data available
no data available
Serious eye damage/irritationno data available
Respiratory or skin sensitizationno data available
Germ cell mutagenicityno data available
CarcinogenicityEvaluation: There is inadequate evidence in humans for the carcinogenicity of phenobarbital. There is sufficient evidence in experimental animals for the carcinogenicity of phenobarbital. Overall evaluation: Phenobarbital is possibly carcinogenic to humans (Group 2B).
Reproductive toxicityno data available
STOT-single exposureno data available
STOT-repeated exposureno data available
Aspiration hazardno data available
12.Ecological information 12.1 Toxicity- Toxicity to fish: LC50; Species: Pimephales promelas (Fathead minnow, age 30 days, mean length 16.5 mm, mena weight 0.067 g); Conditions: flow through, 24.9°C, pH 7.8, hardness 45.1 mg/L CaCO3, alkalinity 108 mg/L CaCO3, dissolved oxygen 6.8 mg/L; Concentration: 484 mg/L for 96 hr (95% confidence limit: 446-526 mg/L) /99+% purity
- Toxicity to daphnia and other aquatic invertebrates: LC50; Species: Daphnia magna (Water flea); Concentration: 1,460 mg/L for 24 hr /Conditions of bioassay not specified
- Toxicity to algae: no data available
- Toxicity to microorganisms: no data available
AEROBIC: Phenobarbital, present at 100 mg/L, reached 0% of its theoretical BOD in 4 weeks using an activated sludge inoculum at 30 mg/L in the Japanese MITI test(1).
12.3 Bioaccumulative potentialAn estimated BCF of 4 was calculated in fish for phenobarbital(SRC), using a log Kow of 1.47(1) and a regression-derived equation(2). According to a classification scheme(3), this BCF suggests the potential for bioconcentration in aquatic organisms is low(SRC).
12.4 Mobility in soilThe Koc of phenobarbital is estimated as 59(SRC), using a log Kow of 1.47(1) and a regression-derived equation(2). According to a classification scheme(3), this estimated Koc value suggests that phenobarbital is expected to have high mobility in soil. The pKa of phenobarbital is 7.3(4), indicating that this compound will exist partially in the anion form in the environment and anions generally do not adsorb more strongly to soils containing organic carbon and clay than their neutral counterparts(5).
12.5 Other adverse effectsno data available
13.Disposal considerations 13.1 Disposal methods ProductThe material can be disposed of by removal to a licensed chemical destruction plant or by controlled incineration with flue gas scrubbing. Do not contaminate water, foodstuffs, feed or seed by storage or disposal. Do not discharge to sewer systems.
Contaminated packagingContainers can be triply rinsed (or equivalent) and offered for recycling or reconditioning. Alternatively, the packaging can be punctured to make it unusable for other purposes and then be disposed of in a sanitary landfill. Controlled incineration with flue gas scrubbing is possible for combustible packaging materials.
14.Transport information 14.1 UN NumberADR/RID: UN2811 | IMDG: UN2811 | IATA: UN2811 |
ADR/RID: TOXIC SOLID, ORGANIC, N.O.S. |
IMDG: TOXIC SOLID, ORGANIC, N.O.S. |
IATA: TOXIC SOLID, ORGANIC, N.O.S. |
ADR/RID: 6.1 | IMDG: 6.1 | IATA: 6.1 |
ADR/RID: III | IMDG: III | IATA: III |
ADR/RID: no | IMDG: no | IATA: no |
no data available
14.7 Transport in bulk according to Annex II of MARPOL 73/78 and the IBC Codeno data available
15.Regulatory information 15.1 Safety, health and environmental regulations specific for the product in questionChemical name | Common names and synonyms | CAS number | EC number |
---|---|---|---|
phenobarbital | phenobarbital | 50-06-6 | none |
European Inventory of Existing Commercial Chemical Substances (EINECS) | Listed. | ||
EC Inventory | Listed. | ||
United States Toxic Substances Control Act (TSCA) Inventory | Not Listed. | ||
China Catalog of Hazardous chemicals 2015 | Not Listed. | ||
New Zealand Inventory of Chemicals (NZIoC) | Listed. | ||
Philippines Inventory of Chemicals and Chemical Substances (PICCS) | Listed. | ||
Vietnam National Chemical Inventory | Not Listed. | ||
Chinese Chemical Inventory of Existing Chemical Substances (China IECSC) | Not Listed. |
Creation Date | Aug 19, 2017 |
---|---|
Revision Date | Aug 19, 2017 |
- CAS: Chemical Abstracts Service
- ADR: European Agreement concerning the International Carriage of Dangerous Goods by Road
- RID: Regulation concerning the International Carriage of Dangerous Goods by Rail
- IMDG: International Maritime Dangerous Goods
- IATA: International Air Transportation Association
- TWA: Time Weighted Average
- STEL: Short term exposure limit
- LC50: Lethal Concentration 50%
- LD50: Lethal Dose 50%
- EC50: Effective Concentration 50%
- IPCS - The International Chemical Safety Cards (ICSC), website: http://www.ilo.org/dyn/icsc/showcard.home
- HSDB - Hazardous Substances Data Bank, website: https://toxnet.nlm.nih.gov/newtoxnet/hsdb.htm
- IARC - International Agency for Research on Cancer, website: http://www.iarc.fr/
- eChemPortal - The Global Portal to Information on Chemical Substances by OECD, website: http://www.echemportal.org/echemportal/index?pageID=0&request_locale=en
- CAMEO Chemicals, website: http://cameochemicals.noaa.gov/search/simple
- ChemIDplus, website: http://chem.sis.nlm.nih.gov/chemidplus/chemidlite.jsp
- ERG - Emergency Response Guidebook by U.S. Department of Transportation, website: http://www.phmsa.dot.gov/hazmat/library/erg
- Germany GESTIS-database on hazard substance, website: http://www.dguv.de/ifa/gestis/gestis-stoffdatenbank/index-2.jsp
- ECHA - European Chemicals Agency, website: https://echa.europa.eu/